On December 19, 2007, GlaxoSmithKline, the largest pharmaceutical company in the UK (NYSE: GSK), completed the acquisition of Reliant Pharmaceuticals for $ 1.65 billion. Reliant, based in New Jersey, USA, has contributed 4 medicines, including Lovaza, to the new owner, which has greatly strengthened the Glaxo cardiovascular medicine treatment business. Lovaza's main active ingredient is omega-2 acid ethyl esters, which are used to treat adult patients with high triglycerides, who are at high risk of developing coronary heart disease. In the first nine months of this year, Lovaza's sales increased 115% year-on-year to $ 206 million. Through the merger, Glaxo has the right to sell Lovaza in the United States and Puerto Rico. Reliant Pharmaceuticals' three other marketed drugs are DynaCric (hypertension), InnoPran (hypertension) and Rythmol (arrhythmia).
     GlaxoSmithKline opens its headquarters in Philadelphia, USA. On December 19, Glaxo's (NYSE: GSK) share price rose by $ 0.14 or 0.28% to close at $ 51.03 / share, and the 52-week trading range was $ 47.49-59.98 / share, with a P / E ratio of 13.36 and a market value of $ 139.4 billion .